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Abstract: Liver cancer treatments are often hindered by poor drug physicochemical properties,
hence there is a need for improvement in order to increase patient survival and outlook. Combination
therapies have been studied in order to evaluate whether increased overall efficacy can be achieved.
This study reports the combined treatment of liver cancer cells with a combination treatment of
chemotherapeutic agent paclitaxel and pro-apoptotic protein cytochrome C. In order to administer
both agents in a single formulation, a poly(allylamine)-based amphiphile has been fabricated with
the incorporation of a hybrid iron oxide-gold nanoparticle into its structure. Here, the insoluble
paclitaxel becomes incorporated into the hydrophobic core of the self-assemblies formed in an aqueous
environment (256 nm), while the cytochrome C attaches irreversibly onto the hybrid nanoparticle
surface via gold-thiol dative covalent binding. The self-assemblies were capable of solubilising up to
0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached
onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core. The formulation
was tested on a panel of liver cancer cells and cytotoxicity was measured. The findings suggested
that indeed a significant improvement in combined therapy (33-fold) was observed when compared
with free drug, which was double the enhancement observed after polymer encapsulation without
the cytochrome C in hepatocellular carcinoma (Huh-7D12) cells. Most excitingly, the polymeric
nanoparticles did result in improved cellular toxicity in human endothelian liver cancer (SK-hep1)
cells, which proved completely resistant to the free drug.
Keywords: combination therapy; drug delivery; liver cancer; paclitaxel; hybrid nanoparticles
1. Introduction
Liver cancer is a devastating disease with around 5700 patients newly diagnosed in the United
Kingdom alone each year [1]. Current treatment regimens often are not effective because of the late
stage of diagnosis and the inability to deliver the correct therapeutic dose to the liver [2]. Over the
past few years, more effort has been concentrated in the development of multifunctional [3–5] or
combination therapy [6–8] in order to improve existing anticancer treatments. This strategy has
previously identified that combination therapy can result in synergy and overall can improve efficacy
of therapies, as well as reduced drug resistance. These studies often focus on the use of two or more
chemotherapy agents which, however, often results in a costly approach that may not be feasible for
the market [9]. In order to overcome these challenges, the use of proteins that can be used to trigger or
program cell death has been explored as an alternative to existing drug entities. Nanotechnologies
have been extensively shown to accumulate within the liver after systemic circulation [10–12].
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This accumulation can be exploited for liver cancers in order to deliver the therapeutic payload
in a site specific manner.
Previously, we demonstrated that by attaching pro-apoptotic protein cytochrome C onto the
surface of hybrid iron oxide-gold nanoparticles (HNPs) and delivering these particulate systems to
liver cancer cells in combination with chemotherapy agents, a synergistic effect resulted in increased
cellular mortality [13,14]. In this study, we aim to prepare a single formulation combining both
cytochrome C and chemotherapy treatment. Our proof of concept studies showed that combined
delivery of HNP surface functionalised with cytochrome C (HNP-c) and paclitaxel (PTX), resulted in
the most notable effects across hepatocellular carcinoma cell line (HepG2), hepatocellular carcinoma
cell line (Huh-7D12), and human endothelial liver cancer (SK-hep-1) cell lines [14]. PTX is a member of
the taxane anti-microtubule drug family, which has exhibited a potent effect in cancer treatment by
targeting the β-tubulin subunit of the microtubule [15]. Here, the PTX binds the tubulin parallel to the
microtubule and increases the polymerization processes. Consequently, conformational changes
at the M-loop part of the β-tubulin and a stable interaction between the proto-filament in the
lateral level are observed. However, because of its poor aqueous solubility, clinical use of PTX is
often hindered [16]. As such, formulations of PTX using amphiphilic polymers have been heavily
reported in the literature [17–20], with some nanoparticle formulations now available in the clinic for
cancer therapy [21].
Unfortunately, it is not possible to directly conjugate PTX onto the gold surface of the HNPs to
co-deliver the drug with cytochrome C. This is because of the fact that there is no obvious mechanism,
such as the presence of thiol or Van der Waal’s interactions, required for direct binding. Additionally,
the highly hydrophobic nature of the PTX molecule would result in the HNPs precipitating out of
solution. Hence, a more sophisticated macromolecular system is required if the HNP-c and PTX are to
be co-delivered in a single platform.
In this work, we report the use of an amphiphilic polymer with HNPs incorporated into its
intrinsic structure for combined delivery of cytochrome C and PTX (Figure 1). The amphiphilic
polymer used is a graft polymer based on an aqueous poly(allylamine) with hydrophobic
5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol (oxadiazole) pendants grafted in a 5% molar ratio onto its
homopolymer backbone, forming poly(allylamine)-oxadiazole (PAA-Ox5). The thiol residues in the
oxadiazole pendants are capable of forming irreversible dative covalent binding with the gold surface
of HNPs. Once in aqueous environments, these amphiphilic structures spontaneously aggregate into
core-shell aggregates because of a reduction in Gibbs’ free energy. It is this spontaneous aggregation
that allows for hydrophobic drug incorporation and solubilisation within the core.
This PAA-Ox5 construct has previously been reported as a magnetomicelle with the potential
for drug solubilisation [22]. Unfortunately, the cytochrome C itself is freely water soluble and, hence,
has no thermodynamic desire to become encapsulated inside the core of the self-assemblies formed.
Hence, in order to produce a single combined therapy platform, HNPs are incorporated into the
intrinsic polymer structure, allowing for both drug solubilisation of the hydrophobic PTX and the
ability to carry cytochrome C as a cargo attached to the HNP surface, which sits inside the core of
the nano-aggregates formed. As far as we are aware, this is the first in kind magnetomicelle used for
combined therapy of cytochrome C and chemotherapies for liver cancer treatment.
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(ATCC, Manassas, VA, USA) (ATCC® HB8065™), SK-hep-1 was from ATCC (ATCC® HTB-52™), 
Huh-7D12 cell line was from ECACC (European Collection of Authenticated Cell Cultures, Porton 
Down, UK), and U937 were purchased from ATCC (ATCC® CRL-3253™). 
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(MW 200,000). Iterative gold coating was achieved by reduction of tetrachloroauric acid onto gold 
seeding on the HNP surface. Metal content was determined using inductively coupled plasma–
optical emission spectroscopy (ICP-OES). The concentration of HNPs used for all experiments 
indicates the concentration of Fe. Maximum ultraviolet (UV) absorbance (λmax) of HNPs was 
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Figure 1. Chemical structure of (A) paclitaxel and (B) poly(allylamine)-oxadiazole (PAA-Ox5)-hybrid
iron oxide-gold nanoparticle (HNP), and molecula structure of (C) cytochrome C and (D)
novel formulation.
2. Materials and ethods
All che icals, unless otherwise stated, were purchased from Sig a-Aldrich (Gillingham, UK),
all solvents and cell culture consumables were purchased from Fisher Scientific (Loughborough,
UK). Hepatocellular carcinoma cell line (HepG-2) were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) (ATCC® HB8065™), SK-hep-1 was from ATCC (ATCC®
HTB-52™), Huh-7D12 cell line was from ECACC (European Collection of Authenticated Cell Cultures,
Porton Down, UK), and U937 were purchased from ATCC (ATCC® CRL-3253™).
2.1. Poly(a lylamine)-oxadiazole (P - x5) t esis t i ti
P - t esized as previously reported [22]. PAA was reacted in 1:0.05 molar feed with
5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol (oxadiazole, Ox) (monomer/penda t). Briefly, PAA was
di solved in 1:1 (v/v) methanol/chlorof rm with stirring, followed by the addition of excess of
triethylamine. The reaction was sti red for 0.5 h at roo te perature. To the poly er solution as
added 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol, dissolved i v) t a l chloroform, in a
drop-wise ma ner over 0.5 h. The reaction was stirred for a further 18 h at 37 ◦C. After his tim ,
the solvent was evaporated and the polymer residue washed 3× with diethyl ether before air drying
overnight. The resultant residue was di solved in deionised water and dialysed (12–14 kDa pore size)
against deionised ater for 24 . The resultant solution as fr - rie . Polymer structure as
characterise using prot n cle r ti s t , 400 z at 25 ◦C) in deuterated
methanol (Bruker, , S ), a tenuated total reflectance-fourier transform infrared spectroscopy
(A -F I ) ( icolette IS50, Ther o-Fisher, o ghboro , ), and ele ental analysis on a Perkin
Elmer series 2 ele ental analyser (Perkin El er, , ).
2.2. HNP Synthesis and Characterisation
HNP synthesis has been well reported previously [23–25]. Briefly, iron oxide (Fe3O4) nanoparticles
were prepared through precipitation reaction and stabilised with poly(ethylenimine) (MW 200,000).
Iterative gold co ting was achieved by reduction of tetrachl roauric acid onto gold seeding
on the HNP surface. Metal content was determined using inductively coupled plasma–optical
emission spectroscopy (ICP-OES). The concentration of HNPs used for all experiments indicates
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the concentration of Fe. Maximum ultraviolet (UV) absorbance (λmax) of HNPs was measured using
a UV-2600 ultraviolet visible (UV-Vis) spectrophotometer with an ISR-2600 Plus Integrated sphere
(Shimadzu, Kyoto, Japan). The samples were scanned in aqueous solution, inside quartz cuvettes
between 400 and 800 nm. The hydrodynamic diameter and polydispersity index were estimated
using photon correlation spectroscopy (PCS) (Zetasizer Nano-ZS, Malvern Instruments, Malvern, UK).
All measurements were carried out at 25 ◦C (n = 3). Zeta potential measurements were carried out to
determine surface charge using the same instrument. Transmission electron microscopy (TEM) was
used to visualise the morphology and diameter of particles on formvar-coated copper grids using a
JEOL JEM-1230 microscope with ANAlysis software (JEOL, Tokyo, Japan).
2.3. PAA-Ox5-HNP Conjugation
A 10 mL solution of 5 mg/mL PAA-Ox5 was prepared with deionised water as the diluent.
The polymer solution was probe sonicated for 10 min. To this solution, 500 µL of HNPs were added
and the mixture was probe sonicated for a further 10 min.
2.4. Characterisation of PAA-Ox5 and PAA-Ox5-HNP Nano-Aggregates
Nano-aggregates were formed in aqueous solution after probe sonication. Solutions were filtered
using 0.45 µm syringe filters prior to analysis. The critical aggregation concentration (CAC) was
determined using a torsion balance. The surface tensions of polymer solutions were measured at
25 ◦C using a torsion balance (OS, White Electrical Instrument Co., London, UK). The platinum ring
and platform were cleaned with ethanol and doubly distilled water prior to analysis of each sample.
The measurement was conducted in triplicate for each polymer solution to obtain an average value.
The surface tension of deionised water was determined between each concentration to ensure no cross
contamination of samples had occurred. Photon correlation spectroscopy, zeta potential measurement,
TEM imaging, and magnetic characterisation was carried out as previously described.
2.5. Attachment of Cytochrome C onto the HNPs in the PAA-Ox5-HNP
PAA-Ox5-HNP (10 mL, 5 mg/mL) was prepared in deionised water, 500 µL of cytochrome C (at
the IC10 of the cytochrome C/0.012 mg/mL, determined previously [14]) was added and the solution
was probe sonicated for 10 min, forming PAA-Ox5-HNP-c. The particles were magnetically separated
from the solution and the amount of attached cytochrome C was quantified indirectly by measuring
levels of non-attached protein. Quantification was carried out using UV-Vis spectrophotometry
(ISR-2600 Shimadzu, Duisburg, Germany) at 410 nm.
2.6. Paclitaxel (PTX) Loading and Release of Nano-Aggregates
PTX (25 mg) was loaded into PAA-Ox5-HNP-c nano-aggregates using probe sonication with a
drug/polymer feed ratio (1:1) for 10 min. The resultant solution was filtered to remove unsolubilised
PTX molecules using a 0.45 µm syringe filter. PTX concentration was determined using reverse
phase high performance liquid chromatography (HPLC) with a mobile phase consisting of 55:45
(v:v) water/acetonitrile using a Perkin Elmer Flexar LC Auto sampler (Perkin Elmer, Waltham, MA,
USA) and a flow rate of 1 mL/min, and analysed using UV detection at 227 nm. All measurements
were performed at room temperature and PTX encapsulation concentration was calculated in respect
to the PTX standard curve. PTX formulation was analysed using photon correlation spectroscopy,
zeta potential, and TEM imaging. The formulation was also freeze-dried for NMR and ATR–FTIR
spectra measurements. PAA-Ox5-HNPc+PTX final formulation was stirred at room temperature in
water for 24 h. At set time points, an external magnetic field was applied and HNPs were collected,
the supernatant solution was sampled and analysed for PTX, as previously described. The samples
were carried out in triplicate and compared to a calibration curve.
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2.7. Biological Characterisation of Nano-Aggregates and Formulations
HepG2, Huh-7D12, SK-hep-1, and U937 cells were grown as a monolayer in Dulbecco’s Modified
Eagle’s Medium (DMEM) culture media (HepG-2 & Huh-7D12), Eagle’s Minimum Essential Medium
(EMEM) media for SK-hep-1, and Roswell Park Memorial Institute (RPMI) media for U937. All media
was supplemented with 10% FBS (fetal bovine serum) and 1% penicillin streptomycin. The cells were
grown in a humidified incubator at 5% CO2 and 37 ◦C. The U937 cells were differentiated with 0.02%
phorbol-12-myristate 13-acetate (PMA) (50 µg/mL in phosphate buffered saline (PBS)) in order to
transform them into macrophage-like cells before testing.
The level of cytotoxicity of the PTX formulation was determined via the 3-[4,5-dimethylthiazol-
2-yl]-2,5diphenyltetrazolium bromide (MTT) assay on the four cell lines over 24 h. Briefly, the cells
were seeded into 96-well plates (15,000 cells/well) and incubated with increasing PTX concentration
(0–1 nM). The plates were incubated for 24 h before the solutions were removed and cells washed with
fresh media. MTT solution (50 µL, 5 mg/mL) was added to the wells and the plate was incubated (37 ◦C
with 5 Männedorf, Switzerland). The percentage viability was calculated relative to the positive and
negative controls (media and Triton-X (1:5 phosphate buffered saline (PBS), respectively). Cytotoxicity
assays for free PTX and PAA-Ox5-HNP-c incorporated PTX were carried out.
Drug uptake studies were carried out after 4 h incubation of the PTX formulation. The cells
were seeded in a six-well plate (50,000 cells/well) and incubated with 50 µg/mL PTX (in formulation
compared with free drug). The plates were incubated for 4 h at 37 ◦C and 5% CO2 before the media
was removed and the cells washed three times with phosphate buffered saline (PBS). The cells were
trypsinised and resuspended in 1 mL media. The cells were counted on a Countess® automated cell
counter (Thermofisher, Loughborough, UK), 100,000 cells were transferred into an Eppendorf tube and
centrifuged at 500 rpm for 5 min. The cell pellet was resuspended in deionised water and vortexed for
30 s. The total intracellular concentration was measured using reverse phase HPLC with UV detection
at 227 nm, using HPLC (Perkin Elmer Flexar LC Autosampler) as previously described. Total drug
concentration was calculated per cell in respect to calibration curves.
All statistical analyses were carried out using t-test analysis within the Microsoft Excel® software
package (Microscoft, Redmond, WA, USA).
3. Results
3.1. Synthesis and Characterisation of PAA-Ox5
The fabrication of PAA-Ox5 was performed via a simple substitution reaction of the primary
amine in the parent PAA structure and the chloride functional group of the oxadiazole compound.
1H NMR spectroscopy confirmed that the comb polymer synthesis was successful (Figure 2A). Peaks
were observed at δ 0.75 ppm, δ 1.40 ppm, δ 1.50 ppm, δ 2.50 ppm and δ 3.00 ppm, which are because
of the CH2 and CH groups in the parent PAA backbone (Figure 2A1), respectively. Additional peaks
were observed at δ 7.25–7.75 ppm after Ox5 conjugation onto the polymer backbone (Figure 2A2).
These were a result of the aromatic CH groups present in the oxadiazole pendant group. The proton
on the –SH group of the oxadiazole pendant was not detected, which is likely to be a result of rapid
exchange between the thiol and the D2O solvent, hence masking the signal.
FTIR analysis of the PAA-Ox5 amphiphile showed characteristic peaks observed at 3273 cm−1
and 2846 cm−1, which are attributed to the N–H stretching and C–H stretching, respectively, in the
PAA backbone (Figure 2B1). After attachment of the Ox5 onto the PAA backbone, an additional peak
was observed at 1597 cm−1 as a result the bending and stretching vibrations of the C=C in the aromatic
ring (Figure 2B2). The surface tension for the PAA amphiphiles, both with and without incorporation
of HNPs, was determined.
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Figure 2. Chemical characterisation of (A1) PAA using proton nuclear magnetic resonance (1H NMR)
spectroscopy, (A2) PAA-Ox5 using proton nuclear magnetic resonance (1H NMR) sp ctroscopy,
(B1) PAA using attenuated total reflectance–fourier transform infrared (FTIR-AT ) t and
(B2) PAA-Ox5 using attenuated total reflectance–fourier transform infrared (F I -ATR) spectroscopy.
3.2. Synthesis and Characterisation HNPs
The metal (Fe and Au) composition of the HNPs was determined using ICP-OES. The data showed
that 2.09 mg/mL of iron and 1.16 mg/mL of gold were present, giving a 2:1 Fe/Au ratio (Table 1).
The particle size, as observed on TEM, was approximately 40 nm and the particulates were spherical in
morphology (Figure 3A). UV-Vis spectroscopy showed a lambda max value of pproximately 600 nm
(Figure 3D), confirming gold coating had been achieved.
Table 1. Physical properties of particles and formulations develope (n = 3, ± standard deviation—SD).
PTX—paclitaxel; HNP—hybrid iron oxide-gold nanoparticle.
Sample
Particle Size Using
Photon Correlation
Spectroscopy, nm
Poly
Dispersity
Index
Metal
Content
Fe/Au
Cytochrome
C Content
mg/mL
PTX
Content
mg/mL
HNP 948 1 2:1 - -
PAA-Ox5 82 0.55 - - -
PAA-Ox5-HNP-c 186 0.137 2:1 0.012 -
PAA-Ox5+PTX 112 0.232 - - 0.598
PAA-Ox5-HNP-c+PTX 256 0.124 2:1 0.012 0.698
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Figure 3. Physical characterisation. Transmission electron microscopy (TEM) images of (A) HNPs,
(B) PAA-Ox5, and (C) PAA-Ox5-HNP. (D) Ultraviolet visible (UV-Vis) spectroscopy of HNPs, (E) surface
tension measurements of amphiphiles, and (F) zeta potential measurement of samples in deionised
water (n = 3, ± standard deviation—SD).
3.3. Characterisation of the Nano-Aggregates
As polymer concentration increases in the aqueous environment a change in surface tension
of the aqueous media is observed. This is a result of the surface layer becoming saturated with
amphiphile, forcing it into the bulk solution and hence initiating aggregation. The critical aggregation
concentration (CAC) is a measure of how stable the aggregates are in solution and gives an indication
of whether they will undergo breakdown after dilution. The surface tension showed that the CAC
for the PAA-Ox5 was 0.313 mg/mL, whereas the HNP containing amphiphile was 0.039 mg/mL
(Figure 3E). This suggested that the aggregates formed at lower concentrations when the magnetic
HNPs were incorporated into the structure. The reason for this is not known, however it may be
possible that the magnetic attractive forces between the HNPs result in stronger attractive forces than
the intermolecular hydrophobic–hydrophobic forces required for aggregation. Hence, these drive
forward aggregation at lower concentrations.
TEM imaging showed the PAA-Ox5 micelles structure of approximately 75 nm in diameter
(Figure 3B). This was much smaller after HNP inclusion into the polymer structure. It was observed
that the aggregated formed from PAA-Ox5-HNP (150 nm, Figure 3C) exhibited a dense core (due to
the HNPs) with an irregular outer polymer shell with hindered ability to form compact aggregates
when compared with the PAA-Ox5. Photon correlation spectroscopy measured particulates of 82 nm
for PAA-Ox5 and 186 nm for PAA-Ox5-HNP (Table 1). The slight variance is because of the difference
between measurement techniques, that is one is carried out on a dry sample and one in solution, with
the hydrophilic corona also being measured. The poly dispersity index of the PAA-Ox5 was found to
be 0.55, which does not indicate that particles are particularly mono-dispersed (Table 1). After addition
of the HNP into the polymer structure, a decrease in polydispersity index (PDI) (0.137) was observed,
indicating that the aggregates formed were much more mono-dispersed; a desirable quality for drug
delivery systems.
The PAA-Ox5 zeta potential was measured to be +38 mV. This highly cationic value is because
of the presence of amine groups in the PAA backbone (Figure 3F). After HNP conjugation, this value
reduced to +17 mV. The reason for this is not known; as we postulate that the HNPs sit inside the
aggregate core, there should be no change to net charge. Perhaps some of the particles appear close to
the shell surface, influencing the surface properties of the aggregates.
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3.4. Quantification of Cytochrome C onto the HNPs in the PAA-Ox5-HNP
The amount of cytochrome C attached to the HNPs inside the PAA-Ox5-HNP aggregates was
measured using UV-Vis spectroscopy at 410 nm. The concentration of the pro-apoptotic protein
was measured to have 100% attached into the formulation. This finding showed that, despite the
nano-aggregate forming the hydrophobic core-shell structure, the dative covalent binding between
the gold of the HNP surface and cysteine in the cytochrome C structure was great enough to pull the
hydrophilic protein inside the self-assembly.
3.5. PTX Loading and Release of Nano-Aggregates
PTX was incorporated into the nano-aggregates via insertion into the hydrophobic core.
Interestingly, the PAA-Ox5-HNP-c nanoparticles resulted in higher levels of encapsulation
(0.684 mg/mL) when compared with the PAA-Ox5 (0.598 mg/mL), as observed in Table 1. This is
probably because of the less compact, larger aggregate formed by the PAA-Ox5-HNP, which possessed
increased capacity for the bulky PTX molecules within their hydrophobic domain. The aqueous
solubility of PTX was increased 700-fold for PAA-Ox5-HNP-c aggregates when compared with its
intrinsic aqueous solubility. The final formulation of PAA-Ox5-HNPc+PTX resulted in a nano-aggregate
measuring approximately 175 nm using TEM (Figure 4A), and 256 nm using photon correlation
spectroscopy (Table 1).
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Figure 4. Properties of PAA-Ox5-HNPc+paclitaxel (PTX) loaded formulations. (A) TEM image of
nano-aggregate and (B) drug release profile over 24 h carried out at room temperature (n = 3, ±SD).
Drug release from PAA-Ox5-HNPc+PTX was measured over 24 h (Figure 4B). The data showed
that a preliminary release of 20% PTX was observed after 20 min, this increased to approximately 40%
after 150 min, no further release was detected over the time-frame tested. Therefore, it is presumed
that this platform may be useful as a delivery system that provides an initial bolus dosage followed by
a steady m inten nce dose. More work is required in order to investigate this potential under more
reali tic physiological conditions.
3.6. Biological Characterisation of Nano-Aggregates and Formulations
Cellular uptake of PTX, both in native form and in the PAA-Ox5-HNP-c formulation,
was measur d in HepG2, Huh-7D12, SK-hep-1 and U937 cell after 4 h, sing ICP-OES. Th data
(Figure 5) showed that drug internalisation levels consistently and significa tly increased afte
capsulation inside the olymer amp iphile when compared with the native form across all
four cell li es. This is likely becau e of the nanoparticl s und goi endocytosis, an extensively
reported mechani m for cellular internalisation of nanomedicines. This process results in much mor
rapid cellular internalisation, as well as allowing greater quantities to b come incorporated into th
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intracellular environments when compared with the conventional mechanisms for drug uptake, such
as permeation through tight junctions, passive transport, etc. Interestingly, the PAA-Ox5 containing
PTX consistently showed significantly reduced drug internalisation levels when compared with the
PAA-Ox5-HNP. As these complex structures form polymeric nano-aggregates with the HNPs inside
the hydrophobic core, it is expected that there should be little difference in their surface properties,
resulting in different internalisation levels. However, the zeta potential data did show a reduction in
surface charge from +38 mV to +17 mV (Figure 3F) upon HNP conjugation. This finding, coupled with
the increased drug loading levels of PAA-Ox5-HNP (Table 1), possibly account for the increased PTX
levels inside all cell lines tested.
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Figure 5. Cellular uptake of PTX in HepG2, Huh-7D12, SK-h and U937 cells after 4 h exposure
to drug alone and in formulation (n = 3, ±SD).  PTX,
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The differentiated U937 cells possessed elevated intracellular PTX concentrations across the board.
This may be because of the nature of these ‘macrophage-like’ cells, internalizing the drug/formulations
in line with their role within biological systems—to seek and destroy.
The cytotoxicity of the PTX-loaded PAA-Ox5-HNP-c amphiphiles on liver cancer cell lines (HepG2,
Huh-7D12, SK-hep-1, and U937) was etected via MTT assay (Figure 6). Serial dilutions of PTX alone
and in combination with the PAA-Ox5-HNP-c formulation for 24 h, 48 h, and 72 h.
After 24 h incubation with HepG2 cells, the IC50 was determined to be 50 nM and 40 nM in the
PTX formulations of PAA-Ox5 and PAA-Ox5-HNP-c, respectively (Table 2). This was a significant
improvement compared with free drug, where no IC50 was observed in the concentration ranges tested.
A similar trend was observed in the Huh-7D12 cells, whereby the PTX alone did not result in 50% loss
in viability, how ver within the nanoparticl formulations, IC50 valu s were determined to be 53 nM
and 11 nM for PTX encapsulated within PAA-Ox5 and PAA-Ox5-HNP-c, respectively. The SK-hep-1
cell line is a notoriously drug resistant cell line, and in keeping with previous findings, there was no
observed IC50 across the concentrations tested for all samples. In general, increasing the exposure time
resulted in a reduction of the IC50 value, as presumably more of the drug entered the cells.
After 72 h exposure in the HepG2 cells, a 31-fold and 43-fold decrease in IC50 of PTX f rmulated in
the PAA-Ox5 and PAA-Ox5-HNP-c formulation, respectively, compared with free drug w s obse ved
(Figure 6A), with similar trends observed in the Huh-7D12 cells (Figure 6B). Again, the SK-hep-1 cell
line proved the most resistant to treatment, with no IC50 being observed after 72 h PTX drug treatment.
However, significant PTX formulations of PAA-Ox5 and PAA-Ox5-HNP-c resulted in cell viability
reduction, with IC50 values observed at 73.32 nM and 57.39 nM, respectively (Figure 6C).
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Interestingly, across the board, the differentiated U937 cells exhibited the greatest reduction of
cell viability after exposure to the drug/formulations (Figure 6D). This is not surprising given the
nature of these cells and their rapid internalisation processes, and does indeed match with the cellular
internalisation data. Additionally, these cells are relatively small in comparison with the other cell
lines, and hence, this coupled with increased PTX intracellular levels may possibly amplify the effect.
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Figure 6. Cytotoxicity of formulations in (A) hepatocellular carcinoma cell line (HepG2), (B) Huh-7D12,
(C) SK-hep-1 and (D) U937 cells after 72 h exposure to PTX alone and after encapsulation inside
amphiphiles (n = 3, ±SD). PTX,  PAA-Ox5+PTX, N PAA-Ox5-HNPc+PTX. * denotes significance
compared to free drug and ** denotes significance compared to PAA-Ox5+PTX, p < 0.01.
Table 2. IC50 values observed over 24–72 h exposure of PTX alone and in formulation in HepG2,
Huh-7D12, SK-hep-1 and U937 cell lines (n = 3, ±SD).
HepG2 Cell Line PTX PAA-Ox5+PTX PAA-Ox5-HNP-c+PTX
24 h - 50 ± 3.05 nM 40 ± 1.5 nM
48 h - 1.99 ± 0.7 nM 0.98 ± 1.3 nM
72 h 32 ± 4.84 nM 1 nM 0.7 nM
Huh-7D12 cell line
24 h - 53 ± 1.52 nM 11 ± 2.5 nM
48 h 37 ± 1.05 µM 4 ± 2.61 nM 2.21 ± 1.82 nM
72 h 31 ± 1.12 µM 3 ± 2.5 nM 0.9 ± 2.1 nM
SK-hep-1 cell line
24 h - - -
48 h - - 84.27 ± 3.1 nM
72 h - 73.32 ± 1.54 nM 57.39 ± 4.02 nM
U937 cell line
24 h - 14 ± 1.5 nM 3.6 ± 0.45 nM
48 h 39 ± 1.72 nM 11 ± 1.29 nM 2.6 ± 0.63 nM
72 h 9 ± 1 nM 1.6 ± 1.08 nM 1.2 ± 2.24 nM
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4. Discussion
Overall, the findings from this study show that formulation of PTX into a nano-sized preparation
did increase the drug efficacy when compared with free PTX. This result is presumably because more of
the drug is entering the cell, as observed in the cellular uptake studies (Figure 5). This is in agreement
with other studies in the literature, whereby, after encapsulation into a polymeric nanoparticle, greater
intracellular trafficking of drug compounds is observed [26–28]. Additionally, formulation of this
practically insoluble drug renders it more clinically useful, as aqueous preparations of injectables are
preferred over oil or organics because of reduced pain on administration, as well as toxic side effects
from the diluents. This is a significant drive within the pharmaceutical arena in order to reformulate
and repurpose existing drug entities, which may be hindered by their physicochemical properties or
indeed may have failed at clinical trial because of these [29,30].
There was significant enhancement in cytotoxic effect observed using the PAA-Ox5-HNP-c
when compared with the PAA-Ox5 (Figure 6). This indicates that the cytochrome C presence
enhances the toxic effect of formulation, as we previously observed [13,14]. These exciting data
show that combination therapy does indeed result in increased overall efficacy. As the relative cost of
cytochrome C is less than for cytotoxic agents, this may serve as a feasible alternative to combining
two chemotherapies. Although, in this study, the combined therapy does not result in huge levels of
synergy, as when the HNP-c and PTX were co-administered as separate preparations previously, it
does give promise that the concept matches the in vitro data—hence, formulation optimisation will
ultimately improve efficacy [14]. The possible reason for the reduced combination efficacy when
compared with the previous work may be because of the use of the cytochrome C at its own IC50
value, which was later diluted across the concentration ranges. It would be more valuable and possibly
result in greater efficacy if this HNP-c was introduced to the cells at a fixed level with only the drug
concentration varied. Further studies are underway to optimise this formulation approach and further
elucidate whether the introduction of cytochrome C into the polymer renders a greater extension of
cytotoxic efficacy on the liver cancer cells. These studies are vital in order to create a sufficient efficacy
enhancement to warrant clinical translation. Additionally, in order to gain a full picture in terms of
cellular toxicity, a non-cancerous liver cell line will also be included in our studies.
The most exciting finding from this data is that the nano-formulation results in much more rapid
cellular uptake compared with PTX alone, presumably because of the initiation of endocytosis. In
cancer, the tissue proliferates so rapidly that every day counts. Often for liver cancer, later diagnosis
occurs due to lack of specific symptoms. Hence, any advancement on a three-day post administration
effect is a success. Here, we saw IC50 values evident after only 24 h—we did not test before this
time point, but looking at the cellular uptake levels after only 4 h, it is likely that this cytotoxic
effect does also occur pre-24 h. The SK-hep-1 cell lines, which proved extremely problematic in our
previous extended study [14], appeared to be much more susceptible to this single macromolecular
nano-formulation when compared with administration of the PTX and HNP-c together. This is a
big achievement and gives hope to overcoming the drug resistance that is already evident in liver
cancer treatment.
5. Conclusions
This platform offers an exciting solution to overcoming the renowned difficulty in the formulation
of PTX, as well as allowing for combination therapy with cytochrome C. Further formulation
optimization is needed in order to fully exploit the synergistic efficacy observed in vitro and, ultimately,
in vivo translation will elucidate the further potential of this platform as a feasible treatment for
liver cancer.
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